At the current price of $3, what is the market’s view of Anixa Biosciences’ future operating performance? To achieve average annual stock market performance of 9.0% over the next 6 years, Anixa Biosciences shares will need to reach $5. Upper quartile performance will require a $6 Anixa Biosciences stock price by 2029.
Executive Summary
- Price Target Research identifies Anixa Biosciences as having: high expected growth, high financial strength, high profitability, and instability.
- Very high valuation, above market shareholder returns. Current valuation levels are very high relative to the Anixa Biosciences Peer Group. Recent market returns have outperformed the Anixa Biosciences Peer Group. Total shareholder returns expected to significantly lag the overall equity market. Based on current investor expectations, Anixa Biosciences shares should reach a level of $0 by 2029 — an -43.1% per year total shareholder return. A 2029 stock price of $5 would reflect median performance and a price of $6 would be required to reach upper quartile performance.
- Anixa Biosciences’ historical growth is average. Historical growth has been average relative to the Anixa Biosciences Peer Group and forecasted growth is relatively very high. Equity Growth has been superior. EPS Growth has lagged. Anixa Biosciences’ historical income statement and balance sheet growth are not available.
- Asset Turnover, and Pretax Margin are group lagging. These factors have negatively affected market perceptions of Anixa Biosciences. The company has an uncertain cash situation, so it will have to work hard to find and fund opportunities.
- Anixa Biosciences’ risk profile is neutral. Overall variability has been very high with very high revenue variability, and only average stock price volatility. Financial Strength is relatively high and earnings’ expectations are very low. The debt/capital ratio has declined.
Be the first to comment